GATC和LifeCodexx宣布，其唐氏綜合癥診斷項(xiàng)目已進(jìn)入臨床驗(yàn)證階段Amresco官網(wǎng)
平臺(tái)授權(quán)一級(jí)代理，咨詢微信：jinshanbio
GATC和LifeCodexx宣布，其唐氏綜合癥診斷項(xiàng)目已進(jìn)入臨床驗(yàn)證階段
德企GATC和LifeCodexx宣布，其唐氏綜合癥診斷項(xiàng)目已進(jìn)入臨床驗(yàn)證階段。該技術(shù)基于二代測(cè)序，屬無(wú)創(chuàng)診斷。初期有望收集150個(gè)樣品，并最終達(dá)到500個(gè)用于驗(yàn)證。他們之前已經(jīng)用38個(gè)樣品在HiSeq測(cè)序平臺(tái)測(cè)試通過(guò)。HiSeq平臺(tái)也是他們的商業(yè)平臺(tái)。另外，F(xiàn)luidigm目前擁有該技術(shù)的專利。Successful start of the clinical validation study of the non-invasive, prenatal diagnostic test for the determination of trisomy 21
28 | 06 | 11
Method based on Illumina HiSeq 2000 validated
In conjunction with several Central European prenatal centers, scientists at GATC Biotech AG andLifeCodexx AGhave begun the clinical validation study of a non-invasive diagnostic test based on next generation sequencing.
The test detects fetal trisomy 21 (Down’s syndrome) and is based on the sequencing cell-free fetal DNA from maternal blood. More than 150 samples could be collected within a short time. At least 500 samples are required for the study. To improve cost efficiency and productivity, the method was successfully validated beforehand on the IlluminaHiSeq 2000 Next Generation Sequencing System with 38 samples.
“Our method allows pooling of at least seven samples for parallel analysis on the HiSeq 2000,” said Dr. Michael Lutz, CEO of LifeCodexx AG, “in this manner we can sink the costs per analyzed sample by more than 50 percent. We are right on our schedule with the validation study and are confident that we will be able to launch the prenatal diagnostic test onto the market as planned at the end of 2011.”
GATC Biotech und LifeCodexx will present the results of their current studies at the World Congress in Fetal Medicine on Malta in June as well as at the Conference of the European Cytogenetics Association in Porto, Portugal, in July.
Contact:
LifeCodexx AG
Dr. Michael Lutz
Chief Executive Officer
m.lutz@lifecodexx.com
+49 (0) 7531 81 60 15GATC Biotech AG
Elke Decker
Director Strategic Marketing & Corporate Communications
e.decker@gatc-biotech.com
授權(quán)一級(jí)代理請(qǐng)認(rèn)準(zhǔn)金山科研平臺(tái)，產(chǎn)品價(jià)格和貨期請(qǐng)咨詢微信：jinshanbio ，詢價(jià)請(qǐng)加微信：jinshanbio
? 如需詢價(jià)，請(qǐng)加客服QQ：1749072012 、客服微信：jinshanbio，或發(fā)送郵件到1749072012@qq.com
? 平臺(tái)為生命科學(xué)研究相關(guān)領(lǐng)域提供一站式耗材試劑儀器解決方案和采購(gòu)服務(wù)，數(shù)據(jù)資源基于CC協(xié)議。
? 本文地址：http://www.5460.com.cn/thread-49861.htm
特別聲明：以上內(nèi)容(如有圖片亦包括在內(nèi))來(lái)源于授權(quán)廠家或網(wǎng)絡(luò)，如有侵權(quán)，請(qǐng)聯(lián)系客服刪除，本平臺(tái)不提供信息校正和存儲(chǔ)服務(wù)。
Notice: The content above (including the pictures if any)comes from authorized manufacturers or networks. In case of infringement, please contact to delete it. This platform does not provide information storage services.
QQ:1749072012